<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>MIC2 is characteristically expressed in lymphoblastic lesions and Ewing's/<z:e sem="disease" ids="C0279980,C0206663" disease_type="Neoplastic Process" abbrv="">primitive neuroectodermal tumor</z:e> <z:hpo ids='HP_0100242'>sarcomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although MIC2 has recently been reported in <z:e sem="disease" ids="C0152276" disease_type="Neoplastic Process" abbrv="">chloroma</z:e> and rare terminal deoxynucleotidyl transferase-positive <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), the incidence and the significance of MIC2 (CD99) immunoreactivity in myeloid lesions is not clear </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we evaluated MIC2 positivity in a variety of myeloid diseases and <z:mpath ids='MPATH_458'>normal</z:mpath> marrow to determine its incidence and distribution in myeloid diseases; its correlation with flow cytometric and cytogenetic data in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; and its association with leukemic transformation, relapse, and <z:e sem="disease" ids="C0152276" disease_type="Neoplastic Process" abbrv="">chloroma</z:e> formation </plain></SENT>
<SENT sid="3" pm="."><plain>Paraffin sections of 11 chloromas and 94 bone marrow core biopsies from 66 patients were stained with CD99 monoclonal antibody 12E7 </plain></SENT>
<SENT sid="4" pm="."><plain>Of 94 bone marrow core biopsies, there were 30 AML (fragment antigen binding M0 to M6), 23 remissions, 5 relapses, 12 <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo>, 13 <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, and 11 <z:mpath ids='MPATH_458'>normal</z:mpath> marrows from patients who did not have <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>CD99 immunoreactivity was evaluated with light microscopy </plain></SENT>
<SENT sid="6" pm="."><plain>MIC2 expression was seen in leukemic blasts in 6 of 11 chloromas (55%) and 13 of 30 AML (43%) but rarely in <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, remission, and <z:mpath ids='MPATH_458'>normal</z:mpath> marrow </plain></SENT>
<SENT sid="7" pm="."><plain>CD99 tended to be positive in M1-, M3-, and HLA-Dr-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and negative in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with relapse </plain></SENT>
<SENT sid="8" pm="."><plain>MIC2 expression did not correlate with the karyotype independent of French-American-British Cooperative Group classification and the disease remission or occurrence of <z:e sem="disease" ids="C0152276" disease_type="Neoplastic Process" abbrv="">chloroma</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>We concluded that MIC2 is commonly expressed in leukemic blasts of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and is not predictive of leukemic transformation from <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> or <z:e sem="disease" ids="C0152276" disease_type="Neoplastic Process" abbrv="">chloroma</z:e> formation </plain></SENT>
<SENT sid="10" pm="."><plain>Caution should be taken when using MIC2 as a marker for Ewing's <z:hpo ids='HP_0100242'>sarcoma</z:hpo>/ <z:e sem="disease" ids="C0279980,C0206663" disease_type="Neoplastic Process" abbrv="">primitive neuroectodermal tumor</z:e> or lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> on paraffin sections of either soft tissue or bone marrow specimens </plain></SENT>
</text></document>